Block Listing Update
22 May 2017
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology today announces that an application has been made to the London Stock Exchange to extend its block listings of securities in respect of a total of 3,360,000 ordinary shares of 0.2 pence each (the "Ordinary Shares") which may arise pursuant to the exercise of options under its Unapproved Share Option Scheme ("USOS") and its EMI Share Option Scheme ("EMI").
Admission of the above additional shares to be block listed is expected to occur on or around 25 May 2017.
The Company makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares.
The table below provides further detail:
|Name of company:||Futura Medical plc|
|Name of scheme(s):||USOS
|Period of return:||From:||25 November 2016|
|To:||22 May 2017|
|Number and class of securities not issued under the scheme(s) at beginning of period||USOS:||1,156,321|
|Number and class of securities admitted to the scheme(s) in the period||USOS:||1,466,208|
|Number of securities issued under the scheme(s) during the period Number of securities lapsed under the scheme(s) during the period||USOS:||(176,419)|
|Balance of securities under the scheme(s) not yet issued at the end of the period||USOS:||2,446,110|
|Number and class of securities originally admitted and the date of admission||USOS:||814,424 on 25 May 2011, 1,202,280 on 8 October 2013,
1,466,208 on 25 May 2017
|EMI:||1,520,576 on 25 May 2011, 1,467,720 on 8 October 2013,
1,893,792 on 25 May 2017
|Name of contact:||Derek Martin, Chief Financial Officer|
|Telephone number of contact:||+44 (0) 1483 685 670|
For further information please contact:
Aubrey Powell / Liz Yong
Tel: +44 (0) 20 7496 3000
For media enquiries please contact:
Mark Court / Sophie Wills /
Stephanie Watson / Tilly Abraham
Tel: +44 (0) 20 7466 5000
Notes to editors:
About Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.